The Use of Meta‐analysis in Pharmacoepidemiology

Berlin, Jesse A.

doi:10.1002/0470842555.ch38

Cited by 5 publications

(1 citation statement)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A statistically significant increased risk of cataracts due to statins was estimated in this meta‐analysis, but the results are associated with significant between‐studies heterogeneity. From a conservative point of view, it is recommended that systematic reviews and meta‐analyses of noninterventional data should be designed to explore sources of heterogeneity among the results rather than to estimate risk measures to support causative associations . Even excluding the study of Lundh and Nilsson , which is the oldest one, this meta‐analysis includes evidence published for nearly a decade, which can hamper comparisons.…”

Section: Discussionmentioning

confidence: 99%

Statins and risk of cataracts: A systematic review and meta‐analysis of observational studies

Alves

Mendes

Marques

2018

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Summary Introduction Two previous meta‐analyses evaluated the risk of cataracts associated with statins, but did not include relevant studies suggesting a cataractogenic effect. Aims The aim of this systematic review and meta‐analysis of observational studies is to evaluate such association considering the latest published evidence. Methods A literature search was conducted to identify observational, comparative studies evaluating the risk of developing cataracts in patients treated with statins. A meta‐analysis was performed to estimate odds ratios (ORs). Results were stratified according to the following studies’ subgroups: design, methodological quality, method of diagnosis of cataract, patients’ age, and median follow‐up. Meta‐regressions evaluated the influence of the following risk factors: smoking, hypertension, corticosteroids, selective serotonin reuptake inhibitors (SSRI), diabetes mellitus, and cardiovascular disease. Results Twenty‐one studies were included. Treatment with statins was associated with an increased risk of cataracts [OR: 1.11 (95% CI: 1.02‐1.21); P = 0.017; I2 = 97.5%]. This risk remained statistically significant among case‐controls, good methodological quality studies, studies with length of follow‐up ≥5 years and those which outcome was cataract surgery. Between‐studies heterogeneity was high among all risk estimates. Meta‐regressions identified an inverse relationship between the risk of cataracts and the proportion of diabetic patients in the studies. Conclusions The results point out an increased risk of cataract development with statins. However, since the magnitude of the effect is low and between‐studies heterogeneity is high, the extent in which these results have impact on the benefit/risk ratio of statins is difficult to ascertain due to the uncertainty of the findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Statins and risk of cataracts: A systematic review and meta‐analysis of observational studies

Alves

Mendes

Marques

2018

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

Epidemiologic Review of the Calcium Channel Blocker Drugs

Kizer¹,

Kimmel²

2001

Arch Intern Med

View full text Add to dashboard Cite

In the setting of soaring popularity, postmarketing studies of calcium channel blockers came to suggest an increase in a variety of major adverse end points. The evidence, however, was largely observational, and large-scale trials capable of addressing the concerns were wanting. Clinical trials now support the safety and efficacy of the long-acting dihydropyridines for patients with both uncomplicated and diabetic hypertension, although conventional therapies and, in the latter case, angiotensin-converting enzyme inhibitors have superior proof of benefit. By contrast, short-acting dihydropyridines should be avoided. In the acute coronary syndromes, beta-blockers remain the treatment of choice; the evidence for nondihydropyridines remains inconclusive. Stable angina calls for beta-blockers as first-line therapy and nondihydropyridines as second-line therapy, whereas in ventricular dysfunction, safety data for nondihydropyridines are lacking. Initial reports of cancer, bleeding, and suicide have been contradicted by subsequent data, making the associations uncertain or unlikely. Remaining questions await completion of ongoing trials to better define the indications for these agents.

show abstract

Managing Drug Safety Issues with Marketed Products

Waller¹,

Tilson

2003

Stephens' Detection of New Adverse Drug Reactions

View full text Add to dashboard Cite

The Use of Meta‐analysis in Pharmacoepidemiology

Cited by 5 publications

References 202 publications

Statins and risk of cataracts: A systematic review and meta‐analysis of observational studies

Statins and risk of cataracts: A systematic review and meta‐analysis of observational studies

Epidemiologic Review of the Calcium Channel Blocker Drugs

Managing Drug Safety Issues with Marketed Products

Contact Info

Product

Resources

About